AcQumen Medical - Lightning Pitch

Why It Matters

Continuous, needle‑free cardiac output monitoring could dramatically improve outcomes and reduce costs in pediatric intensive care.

Key Takeaways

• Founder’s personal ICU experience sparked Acumen Medical’s mission.
• Ultratra merges impedance and miniature ultrasound for continuous cardiac output monitoring.
• Device provides needle‑free, catheter‑free hemodynamic data for infants.
• Clinical trials launching at top children’s hospitals nationwide.
• Real‑time precision medicine aims to improve outcomes for vulnerable patients.

Summary

Acumen Medical’s founder, an engineer with 19 years in cardiac devices, launched a lightning‑pitch after a personal crisis: his four‑month‑old son required intensive‑care ventilation in early 2023. The experience motivated him to address a critical gap in pediatric cardiac monitoring.

The company’s patented Ultratra device fuses electrical impedance with a miniature ultrasound sensor to deliver continuous, actionable hemodynamic data without needles or catheters. This technology promises real‑time cardiac output measurement for the smallest, most vulnerable patients, a capability currently unavailable.

Children’s hospitals participating in early clinical studies have called Ultratra a ‘game‑changer,’ echoing the founder’s claim that ‘the smallest patients deserve real‑time precision medicine.’ The device’s non‑invasive approach could reduce reliance on invasive lines and improve bedside decision‑making.

If validated, Ultratra could reshape pediatric intensive‑care protocols, opening a new market for non‑invasive monitoring and potentially lowering morbidity and costs associated with invasive monitoring methods.